Cel-sci announces $1.35 million underwritten confidentially marketed public offering of common stock

Vienna, va.--(business wire)---- $cvm--cel-sci corporation (“cel-sci” or the “company”) (nyse american: cvm), a phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share. the closing of the offering is expected to take place on or about may 2, 2023, subject to the satisfaction of customary closing conditions. in addition, the company expects to grant the underwrit.
CVM Ratings Summary
CVM Quant Ranking